HK1064951A1 - Use of poly-glu, tyr for neuroprotection therapy of the cns or pns poly-glu - Google Patents
Use of poly-glu, tyr for neuroprotection therapy of the cns or pns poly-gluInfo
- Publication number
- HK1064951A1 HK1064951A1 HK04107851.9A HK04107851A HK1064951A1 HK 1064951 A1 HK1064951 A1 HK 1064951A1 HK 04107851 A HK04107851 A HK 04107851A HK 1064951 A1 HK1064951 A1 HK 1064951A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- poly
- glu
- tyr
- cns
- pns
- Prior art date
Links
- 230000004112 neuroprotection Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 abstract 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 2
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003292 glue Substances 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46432—Nervous system antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/893,344 US6835711B2 (en) | 2001-06-28 | 2001-06-28 | Use of poly-Glu,Tyr for neuroprotective therapy |
PCT/IL2002/000517 WO2003002140A1 (fr) | 2001-06-28 | 2002-06-27 | Utilisation de poly-glu, tyr et cellules t traitees avec ceux-ci pour une therapie neuroprotectrice |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1064951A1 true HK1064951A1 (en) | 2005-02-08 |
Family
ID=25401407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK04107851.9A HK1064951A1 (en) | 2001-06-28 | 2004-10-12 | Use of poly-glu, tyr for neuroprotection therapy of the cns or pns poly-glu |
Country Status (16)
Country | Link |
---|---|
US (1) | US6835711B2 (fr) |
EP (1) | EP1406650B1 (fr) |
JP (1) | JP4434729B2 (fr) |
KR (1) | KR20040032825A (fr) |
CN (1) | CN1326560C (fr) |
AT (1) | ATE412419T1 (fr) |
AU (1) | AU2002345323B2 (fr) |
CA (1) | CA2451521C (fr) |
DE (1) | DE60229639D1 (fr) |
DK (1) | DK1406650T3 (fr) |
ES (1) | ES2315371T3 (fr) |
HK (1) | HK1064951A1 (fr) |
IL (1) | IL159535A0 (fr) |
MX (1) | MXPA03011926A (fr) |
NZ (1) | NZ530261A (fr) |
WO (1) | WO2003002140A1 (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004060266A2 (fr) * | 2003-01-07 | 2004-07-22 | Yeda Research And Development Co. Ltd. | Vaccin sous forme de gouttes ophtalmiques contenant le copolymere poly-ye pour l'immunisation therapeutique |
US7399740B2 (en) * | 2001-06-28 | 2008-07-15 | Yeda Research And Development Co. Ltd. | Poly-Glu,Tyr for neuroprotective therapy |
DK1429800T3 (da) * | 2001-12-06 | 2009-04-27 | Yeda Res & Dev | Vaccine og anvendelse deraf til behandling af amyotrofisk lateral sklerose |
CA2529488A1 (fr) * | 2003-06-16 | 2004-12-23 | Kyushu Tlo Company, Limited | Methode permettant de produire des cellules immunocompetentes d'origine humaine |
US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
WO2005055920A2 (fr) * | 2003-12-09 | 2005-06-23 | Yeda Research And Development Co. Ltd. | Compositions et methodes de traitement de troubles psychiatriques |
PL1701730T3 (pl) * | 2003-12-09 | 2014-04-30 | Yeda Res & Dev | Sposób i szczepionka zawierająca kopolimer 1 do leczenia zaburzeń psychicznych |
CA2588908C (fr) * | 2004-11-29 | 2014-09-23 | Yeda Research And Development Co. Ltd | Induction de neurogenese et therapie par cellules souches en combinaison avec le copolymere 1 |
US9220813B2 (en) * | 2005-04-18 | 2015-12-29 | Holy Cross Hospital, Inc. | Cell therapy for limiting overzealous inflammatory reactions in tissue healing |
US20100272787A1 (en) * | 2007-12-21 | 2010-10-28 | Ben Gurion University Of The Negev | Amethod of treating neurodegenerative diseases |
WO2009124170A1 (fr) * | 2008-04-04 | 2009-10-08 | The Cleveland Clinic Foundation | Utilisation de greffons de gaine épineurale pour régénération et protection neurale |
WO2010071862A1 (fr) * | 2008-12-19 | 2010-06-24 | Ethicon, Incorporated | Cellules extraites du tissu du cordon ombilical pour le traitement de douleur neuropathique et de la spasticité |
CN102498204B (zh) | 2009-03-26 | 2015-02-04 | 德普伊新特斯产品有限责任公司 | 人脐带组织细胞作为用于阿尔茨海默病的疗法 |
EP2473193A4 (fr) * | 2009-09-04 | 2013-05-01 | Cleveland Clinic Foundation | Procédés d'ingénierie de tissu neural |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
CN102686235A (zh) | 2010-01-04 | 2012-09-19 | Mapi医药公司 | 包含格拉默或其药用盐的储药系统 |
US8377885B2 (en) | 2010-01-04 | 2013-02-19 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
ES2601892T3 (es) | 2011-04-21 | 2017-02-16 | Mapi Pharma Limited | Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes |
EP3600553A4 (fr) | 2017-03-26 | 2020-09-02 | Mapi Pharma Ltd. | Systèmes de dépôt de glatiramère pour le traitement de formes progressives de sclérose en plaques |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002500199A (ja) | 1998-07-21 | 2002-01-08 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | 活性化t細胞、及びそれらの用途 |
-
2001
- 2001-06-28 US US09/893,344 patent/US6835711B2/en not_active Expired - Fee Related
-
2002
- 2002-06-27 DK DK02743592T patent/DK1406650T3/da active
- 2002-06-27 CN CNB028165462A patent/CN1326560C/zh not_active Expired - Fee Related
- 2002-06-27 KR KR10-2003-7016949A patent/KR20040032825A/ko not_active Application Discontinuation
- 2002-06-27 WO PCT/IL2002/000517 patent/WO2003002140A1/fr active Application Filing
- 2002-06-27 ES ES02743592T patent/ES2315371T3/es not_active Expired - Lifetime
- 2002-06-27 MX MXPA03011926A patent/MXPA03011926A/es active IP Right Grant
- 2002-06-27 NZ NZ530261A patent/NZ530261A/en not_active IP Right Cessation
- 2002-06-27 EP EP02743592A patent/EP1406650B1/fr not_active Expired - Lifetime
- 2002-06-27 JP JP2003508379A patent/JP4434729B2/ja not_active Expired - Fee Related
- 2002-06-27 DE DE60229639T patent/DE60229639D1/de not_active Expired - Lifetime
- 2002-06-27 CA CA2451521A patent/CA2451521C/fr not_active Expired - Fee Related
- 2002-06-27 AU AU2002345323A patent/AU2002345323B2/en not_active Ceased
- 2002-06-27 AT AT02743592T patent/ATE412419T1/de not_active IP Right Cessation
- 2002-06-27 IL IL15953502A patent/IL159535A0/xx unknown
-
2004
- 2004-10-12 HK HK04107851.9A patent/HK1064951A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2451521C (fr) | 2011-05-17 |
CN1547482A (zh) | 2004-11-17 |
ATE412419T1 (de) | 2008-11-15 |
DK1406650T3 (da) | 2009-03-02 |
KR20040032825A (ko) | 2004-04-17 |
EP1406650A1 (fr) | 2004-04-14 |
JP2005502616A (ja) | 2005-01-27 |
MXPA03011926A (es) | 2004-03-26 |
JP4434729B2 (ja) | 2010-03-17 |
DE60229639D1 (de) | 2008-12-11 |
NZ530261A (en) | 2006-06-30 |
US6835711B2 (en) | 2004-12-28 |
WO2003002140A1 (fr) | 2003-01-09 |
US20030003082A1 (en) | 2003-01-02 |
IL159535A0 (en) | 2004-06-01 |
AU2002345323B2 (en) | 2006-12-21 |
CN1326560C (zh) | 2007-07-18 |
CA2451521A1 (fr) | 2003-01-09 |
ES2315371T3 (es) | 2009-04-01 |
EP1406650B1 (fr) | 2008-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1064951A1 (en) | Use of poly-glu, tyr for neuroprotection therapy of the cns or pns poly-glu | |
HK1084034A1 (en) | Eye-drop vaccine containing copolymer 1 for therapeutic immunization | |
MY118283A (en) | 6-phenyl-pyridin-2-ylamine derivatives | |
HK1071890A1 (en) | Spiroazacyclic compounds as monoamine receptor modulators | |
AP1869A (en) | b2- Adrenergic receptor agonists. | |
MXPA05009359A (es) | Tetrahidroisoquinolinas 2,5- y 2,6 substituidas para uso como moduladores 5-ht6. | |
AU4331400A (en) | Neurotrophic substituted pyrimidines | |
YU42302A (sh) | Agonisti beta2-adrenergičnih receptora | |
SI1545537T1 (sl) | Agonisti alfa-7 nikoninskega receptorja in statini v kombinaciji | |
TW200640944A (en) | VGF polypeptides and methods of treating VGF-related disorders | |
MXPA02012249A (es) | Peptidos, composiciones y metodos para el tratamiento de burkholderia cepacia. | |
MX351062B (es) | Proteinas de fusion para el tratamiento del snc. | |
WO2000032765A3 (fr) | Ribozymotherapie destinee au traitement et/ou a la prevention de la restenose | |
MXPA03007380A (es) | Derivados de imidazol 2-tio sustituidos y el uso de los mismos en la industria farmaceutica. | |
WO2003105750A3 (fr) | Cellules presentatrices d'antigene pour la neuroprotection et la regeneration nerveuse | |
MXPA03010406A (es) | Tratamiento novedoso para el desorden obsesivo-compulsivo (ocd) y desordenes relacionados con ocd. | |
IL144199A0 (en) | Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions | |
MXPA02000680A (es) | Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf. | |
AU2003215190A8 (en) | Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules. | |
MXPA02012894A (es) | Catecoles nitrados substituidos, su uso en el tratamiento de algunos trastornos del sistema nervioso central y periferico y composiciones farmaceuticas que los contienen. | |
WO2002076930A3 (fr) | Stimulateurs de l'apoptose à médiation des fas à base de diarylurées substituées | |
WO2004087873A3 (fr) | Methodes de traitement de la xerostomie et de la xerophtalmie | |
EP1406605A4 (fr) | Carbamates de 1,2-ethanediols 2-heterocycliques | |
AU2003202255A8 (en) | Compositions for treatment of central nervous system neoplasms, and methods of making and using the same | |
BG105549A (en) | Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20130627 |